Advantage Trust Company’s AbbVie ABBV Stock Holding History

Advantage Trust Company’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$236K	Buy	939 +125	+15%	+$26.9K	0.08%	56
2026 Q1	$177K	Hold	814	–	–	0.08%	46
2025 Q4	$186K	Sell	814 -350	-30%	-$79.7K	0.08%	46
2025 Q3	$270K	Sell	1,164 -500	-30%	-$102K	0.12%	52
2025 Q2	$309K	Sell	1,664 -19	-1%	-$3.53K	0.15%	52
2025 Q1	$353K	Sell	1,683 -26	-2%	-$5.05K	0.21%	32
2024 Q4	$304K	Sell	1,709 -135	-7%	-$24.8K	0.18%	34
2024 Q3	$364K	Hold	1,844	–	–	0.25%	30
2024 Q2	$316K	Hold	1,844	–	–	0.23%	34
2024 Q1	$336K	Hold	1,844	–	–	0.25%	33
2023 Q4	$286K	Buy	+1,844	New	+$269K	0.23%	34

Other funds holding ABBV

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

HCM

Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

FWCM

Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Advantage Trust Company's ABBV Position: Q2 2026 in Review

Advantage Trust Company increased its AbbVie (ABBV) stake by 15% in Q2 2026, buying an estimated $26.9K and bringing the position to 939 shares worth $236K. The position accounts for 0.08% of the portfolio, ranked #56.

Advantage Trust Company first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. The position peaked at $364K in Q3 2024. 1,483 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Advantage Trust Company held 939 shares of AbbVie worth $236K as of Q2 2026.
Advantage Trust Company bought 125 AbbVie shares in Q2 2026, an estimated $26.9K.
AbbVie made up 0.08% of Advantage Trust Company's portfolio in Q2 2026, its #56 holding.
Advantage Trust Company first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
Advantage Trust Company's AbbVie position peaked at $364K in Q3 2024.
1,483 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Advantage Trust Company's 13F filing for Q2 2026, filed 17 Jul 2026.